BioAdaptives

BioAdaptives EBIT CAGR 5Y

The EBIT CAGR (5 Year) of BioAdaptives (BDPT) as of Oct 29, 2026 is 32.59 %. In the previous year, EBIT CAGR (5 Year) was 32.59 % — a change of 0.00% (lower).

EBIT CAGR 5Y

32.59 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of BioAdaptives is 2025 32.59 % . EBIT CAGR (5 Year) of BioAdaptives was 2024 32.59 % . It decreases by 0.00% lower compared to the previous year.

The BioAdaptives EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2018
32.59 USD
Jan 1, 2019
32.59 USD
Jan 1, 2020
32.59 USD
Jan 1, 2021
32.59 USD
Jan 1, 2022
32.59 USD
Jan 1, 2023
32.59 USD
Jan 1, 2024
32.59 USD
Jan 1, 2025
32.59 USD
The BioAdaptives EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %0.00%
32.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

EBIT CAGR (5 Year) of BioAdaptives is 32.59 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s BioAdaptives historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BioAdaptives

All Key Metrics — BioAdaptives